Hermans Greet, Wilmer Alexander, Meersseman Wouter, Milants Ilse, Wouters Pieter J, Bobbaers Herman, Bruyninckx Frans, Van den Berghe Greet
Medical Intensive Care Unit, Department of Internal Medicine, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Am J Respir Crit Care Med. 2007 Mar 1;175(5):480-9. doi: 10.1164/rccm.200605-665OC. Epub 2006 Nov 30.
Critical illness polyneuropathy/myopathy causes limb and respiratory muscle weakness, prolongs mechanical ventilation, and extends hospitalization of intensive care patients. Besides controlling risk factors, no specific prevention or treatment exists. Recently, intensive insulin therapy prevented critical illness polyneuropathy in a surgical intensive care unit.
To investigate the impact of intensive insulin therapy on polyneuropathy/myopathy and treatment with prolonged mechanical ventilation in medical patients in the intensive care unit for at least 7 days.
This was a prospectively planned subanalysis of a randomized controlled trial evaluating the effect of intensive insulin versus conventional therapy on morbidity and mortality in critically ill medical patients. All patients who were still in intensive care on Day 7 were screened weekly by electroneuromyography. The effect of intensive insulin therapy on critical illness polyneuropathy/myopathy and the relationship with duration of mechanical ventilation were assessed.
Independent of risk factors, intensive insulin therapy reduced incidence of critical illness polyneuropathy/myopathy (107/212 [50.5%] to 81/208 [38.9%], p = 0.02). Treatment with prolonged (> or = 14 d) mechanical ventilation was reduced from 99 of 212 (46.7%) to 72 of 208 (34.6%) (p = 0.01). This was statistically only partially explained by prevention of critical illness polyneuropathy/myopathy.
In a subset of medical patients in the intensive care unit for at least 7 days, enrolled in a randomized controlled trial of intensive insulin therapy, those assigned to intensive insulin therapy had a reduced incidence of critical illness polyneuropathy/myopathy and were treated with prolonged mechanical ventilation less frequently.
危重病性多发性神经病/肌病会导致肢体和呼吸肌无力,延长机械通气时间,并延长重症监护患者的住院时间。除了控制风险因素外,尚无特异性预防或治疗方法。最近,强化胰岛素治疗在外科重症监护病房预防了危重病性多发性神经病。
探讨强化胰岛素治疗对入住重症监护病房至少7天的内科患者多发性神经病/肌病及机械通气时间延长的影响。
这是一项前瞻性计划的亚组分析,该随机对照试验评估强化胰岛素与传统治疗对危重病内科患者发病率和死亡率的影响。所有在第7天仍在重症监护的患者每周通过神经肌电图进行筛查。评估强化胰岛素治疗对危重病性多发性神经病/肌病的影响及其与机械通气时间的关系。
独立于风险因素,强化胰岛素治疗降低了危重病性多发性神经病/肌病的发生率(从212例中的107例[50.5%]降至208例中的81例[38.9%],p = 0.02)。机械通气时间延长(≥14天)的治疗率从212例中的99例(46.7%)降至208例中的72例(34.6%)(p = 0.01)。从统计学角度来看,这只是部分地由危重病性多发性神经病/肌病的预防所解释。
在一项强化胰岛素治疗的随机对照试验中,入住重症监护病房至少7天的部分内科患者中,接受强化胰岛素治疗的患者危重病性多发性神经病/肌病的发生率降低,接受机械通气时间延长治疗的频率也较低。